FundaMental Pharma appoints Dr. Dirk Beher as Chief Executive Officer [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
Highly experienced biotech executive, with over a quarter of a century of CNS drug discovery experience Dr. Beher takes over the role of Chief Executive Officer from co-founder Dr. Thomas Schulze FundaMental Pharma recently raised additional seed funding from new investor, the Novartis Venture Fund, bringing its total seed financing to €12.7 million Heidelberg, Germany, 11 April 2024 – FundaMental Pharma GmbH (‘FundaMental' or ‘The Company'), a neuroscience company developing first-in-class small molecule inhibitors for the treatment of a range of neurodegenerative diseases, is pleased to announce the appointment of Dr. Dirk Beher as Chief Executive Officer and Executive Board member. Dr. Beher assumes this role from Dr. Thomas Schulze, who co-founded FundaMental and has been at the helm since its inception. Dr. Schulze will transition to the Board of Directors as part of a carefully planned succession strategy. Dr. Beher brings a wealth of experience to FundaMental, having s
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Amgen Inc. (NASDAQ: AMGN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending [Seeking Alpha]Seeking Alpha
- Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at UBS Group AG from $284.00 to $307.00. They now have a "neutral" rating on the stock.MarketBeat
- Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Morgan Stanley from $271.00 to $310.00. They now have an "equal weight" rating on the stock.MarketBeat
- Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Royal Bank of Canada from $332.00 to $328.00. They now have an "outperform" rating on the stock.MarketBeat
AMGN
Earnings
- 5/2/24 - Beat
AMGN
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- AMGN's page on the SEC website